dual agonist glp 1 and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Unveiling Tirzepatide's Therapeutic Spectrum: A

Data are presented as medians (interquartile ranges) or frequencies (%), and Wilcoxon signed-rank tests and Mann-Whitney U tests were used for paired and nonpaired group comparisons, respectively

By Michael S

The analysis spanned data from January 1, 2015, to December 31, 2023

In the search for novel treatment strategies for alcohol use disorder (AUD), glucagonlike peptide1 (GLP1) receptor agonists (GLP1RAs) approved for treating Type 2 diabetes and obesity have caught much attention

Years after approving three glucagon-like peptide-1 (GLP-1) receptor agonists to treat obesity, the U.S

NP-supervised, in-person care